Anticoagulant News and Research

RSS
Experts identify a novel fucosylated heparan sulfate from the midgut gland of the Japanese scallop

Experts identify a novel fucosylated heparan sulfate from the midgut gland of the Japanese scallop

Case study: Experimental lecanemab treatment causes adverse outcomes in 65-year-old woman with Alzheimer's disease

Case study: Experimental lecanemab treatment causes adverse outcomes in 65-year-old woman with Alzheimer's disease

Extended ECG monitoring of patients with hypertrophic cardiomyopathy detects more arrhythmias

Extended ECG monitoring of patients with hypertrophic cardiomyopathy detects more arrhythmias

Study offers novel insights into reducing adverse effects of antibiotics on the gut microbiome

Study offers novel insights into reducing adverse effects of antibiotics on the gut microbiome

Is there an association between COVID-19 and the risk of developing an autoimmune disease?

Is there an association between COVID-19 and the risk of developing an autoimmune disease?

A randomized trial of a blood thinner after severe COVID-19 to prevent clotting events

A randomized trial of a blood thinner after severe COVID-19 to prevent clotting events

Venous thromboembolism is rare among non-hospitalized COVID-19 patients

Venous thromboembolism is rare among non-hospitalized COVID-19 patients

Non-critically ill hospitalized Covid-19 patients could substantially benefit from a higher dose of blood-thinners

Non-critically ill hospitalized Covid-19 patients could substantially benefit from a higher dose of blood-thinners

Researchers report two unusual COVID-19-related arrhythmic cases in children

Researchers report two unusual COVID-19-related arrhythmic cases in children

Early intervention key to managing diabetes, cardiorenal, and metabolic diseases

Early intervention key to managing diabetes, cardiorenal, and metabolic diseases

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Review on nanoparticles usage for treating thrombosis induced by SARS-CoV-2 infections

Review on nanoparticles usage for treating thrombosis induced by SARS-CoV-2 infections

No benefit of low dose apixaban following acute COVID-19

No benefit of low dose apixaban following acute COVID-19

Natural material derived from seaweed can help improve outcomes after heart bypass surgery

Natural material derived from seaweed can help improve outcomes after heart bypass surgery

Oral anticoagulant does not help patients recovering from moderate and severe COVID-19

Oral anticoagulant does not help patients recovering from moderate and severe COVID-19

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.